Andres T. Blei – 30 December 2003

Xavier Forns, Sergi Ampurdanès, Josep M. Llovet, John Aponte, Llorenç Quintó, Eva Martínez‐Bauer, Miquel Bruguera, Jose Maria Sánchez‐Tapias, Juan Rodés – 30 December 2003 – Liver biopsy is required for staging hepatic fibrosis in patients with chronic hepatitis C, but it is an expensive procedure with occasional complications and poor patient acceptance. This cohort study was designed to assess the accuracy of a noninvasive method aimed to discriminate between patients with and without significant liver fibrosis (stages 2‐4 versus 0‐1).

Giovanna M. Ledda‐Columbano, Monica Pibiri, Danilo Concas, Costanza Cossu, Marco Tripodi, Amedeo Columbano – 30 December 2003 – Cyclin D1 is considered to play a critical role in the progression from G1 to S phase of the cell cycle, and its overexpression is seen in many human tumors. However, previous studies in cell lines have shown that cyclin D1 is not sufficient to trigger cell replication.

Jules L. Dienstag – 30 December 2003 – The report of the 1997 National Institutes of Health Consensus Development Conference on hepatitis C endorsed pretreatment liver biopsy. We revisit the following questions: Does liver histology help determine the urgency of, and predict the likelihood of response to, antiviral therapy, and can surrogate markers supplant histological assessment?

Eve A. Roberts, Latifa Yeung – 30 December 2003 – Mother‐to‐infant transmission of hepatitis C virus (HCV) is comparatively uncommon. The prevalence of antibody to HCV (anti‐HCV) in pregnant women is 0.1% to 2.4%, although in some endemic areas it is much higher. The proportion of women with anti‐HCV who have active infection with viremia is 60% to 70%. Transmission of HCV occurs only when serum HCV RNA is detectable and may be related to higher levels (above 106 copies per mL). The rate of mother‐to‐infant transmission is 4% to 7% per pregnancy in women with HCV viremia.

Gary L. Davis – 30 December 2003 – Alpha interferon therapy of chronic hepatitis C is typically accompanied by a biphasic decrease in hepatitis C virus (HCV) RNA levels: an initial rapid decline during the first 24 to 48 hours, and a second more gradual decline during the following weeks. The rate of second‐phase decline correlates with ultimate response to interferon treatment. Thus, assessment of early virological response (EVR) may predict outcome.

Leonhard Mohr, Julia I. Schauer, Raymond H. Boutin, Darius Moradpour, Jack R. Wands – 30 December 2003 – Gene therapy approaches for the treatment of malignant tumors will require high‐level expression of therapeutic genes in tumors compared with normal tissues. This may be achieved either by targeted gene delivery to tumor cells or by the use of tumor‐specific promoters.

Jean Henrion, Philippe Minette, Lucien Colin, Michael Schapira, Andre Delannoy, Francis R. Heller – 30 December 2003 – Out of a prospective series of 142 consecutive episodes of hypoxic (ischemic) hepatitis (HH), we identified 17 episodes associated with an acute exacerbation of chronic respiratory failure (CRF) without left cardiac failure.

Thomas M. Berghaus, Andreas Baron, Andreas Geier, Rolf Lamerz, Gustav Paumgartner, Peter Conzen – 30 December 2003

Piotr Milkiewicz, Charles O. Mills, Marcelo G. Roma, Jalal Ahmed‐Choudhury, Elwyn Elias, Roger Coleman – 30 December 2003 – The monohydroxy bile acid, taurolithocholate (TLC), causes cholestasis in vivo and in isolated perfused livers. It is also cholestatic in vitro and, in this study using isolated rat hepatocyte couplets, causes a reduction of the accumulation of (fluorescent) bile acid in the canalicular vacuoles (cVA) of this polarized cell preparation.